{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:34:11Z","timestamp":1792787651372,"version":"4.5.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National Institute of Drug Abuse","award":["R25 DA020537"],"award-info":[{"award-number":["R25 DA020537"]}],"id":[{"id":"https:\/\/ror.org\/00fq5cm18","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tobacco use remains a leading preventable cause of morbidity and mortality. Although several pharmacotherapies and behavioral treatments for tobacco use disorder (TUD) exist, their overall efficacy is modest, underscoring the need for innovative treatment approaches. Ketamine, a rapid-acting glutamate receptor antagonist with neuroplasticity-enhancing properties, has shown promise in the treatment of other substance use disorders. Combining ketamine with motivational enhancement therapy (MET) may complement behavioral treatment in TUD by facilitating cognitive and psychological flexibility while strengthening individuals\u2019 ability to quit smoking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The primary aim of this open-label pilot study was to evaluate the feasibility and preliminary clinical outcomes of ketamine treatments delivered in conjunction with MET for smoking cessation in individuals with TUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Seven cigarette smokers (ages 29\u201364) with a history of unsuccessful quit attempts underwent three weekly intramuscular ketamine sessions (0.71\u2009mg\/kg) combined with MET. Feasibility, the primary outcome, was assessed by study completion rates. Secondary outcomes included changes in smoking patterns, craving, nicotine dependence, withdrawal, and motivation to quit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All participants completed the interventional sessions. Ketamine sessions were well-tolerated, and no adverse events other than the expected transient psychoactive effects were observed. Cigarette consumption decreased, accompanied by reductions in nicotine craving. Withdrawal symptoms, nicotine dependence severity, and motivation to quit remained stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ketamine-enhanced psychotherapy for TUD was feasible and was associated with reductions in smoking and craving. These preliminary findings support further trials investigating ketamine\u2019s potential to enhance behavioral interventions for addiction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261488486","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:22:34Z","timestamp":1790338954000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-3386","authenticated-orcid":false,"given":"Jennifer","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Redding","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Amador","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaiser Permanente, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Aleksandrova LR Phillips AG (2021) Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences 42(11): 929\u2013942. https:\/\/doi.org\/10.1016\/j.tips.2021.08.003","DOI":"10.1016\/j.tips.2021.08.003"},{"key":"e_1_3_2_3_1","author":"Annis H","year":"1988","unstructured":"Annis H, Graham JM (1988) Situational Confidence Questionnaire (SCQ): User\u2019s Guide. Addiction Research Foundation.","journal-title":"Situational Confidence Questionnaire (SCQ): User\u2019s Guide"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Azhari N Hu H O\u2019Malley KY et al. (2021) Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study. The American Journal of Drug and Alcohol Abuse 47(1): 92\u201397. https:\/\/doi.org\/10.1080\/00952990.2020.1808982","DOI":"10.1080\/00952990.2020.1808982"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Cahill K Stevens S Lancaster T (2014) Pharmacological treatments for smoking cessation. JAMA 311(2): 193\u2013194. https:\/\/doi.org\/10.1001\/jama.2013.283787","DOI":"10.1001\/jama.2013.283787"},{"key":"e_1_3_2_6_1","unstructured":"Centers for Disease Control and Prevention (2024) Economic trends in tobacco. Available at: https:\/\/www.cdc.gov\/tobacco\/data_statistics\/fact_sheets\/economics\/econ_facts\/index.htm (accessed 1 May 2025)."},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Chuang J Lide RC Kamath N et al. (2026) A pilot study of ketamine among individuals with tobacco use disorder: tolerability and initial impact on tobacco use outcomes. Journal of Addictive Diseases 44(1): 83\u201387. https:\/\/doi.org\/10.1080\/10550887.2025.2450129","DOI":"10.1080\/10550887.2025.2450129"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Clements JA Nimmo WS Grant IS (1982) Bioavailability pharmacokinetics and analgesic activity of ketamine in humans. Journal of Pharmaceutical Sciences 71(5): 539\u2013542. https:\/\/doi.org\/10.1002\/jps.2600710516","DOI":"10.1002\/jps.2600710516"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Dakwar E Levin F Foltin RW et al. (2014) The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biological Psychiatry 76(1): 40\u201346. https:\/\/doi.org\/10.1016\/j.biopsych.2013.08.009","DOI":"10.1016\/j.biopsych.2013.08.009"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Dakwar E Nunes EV Hart CL et al. (2019) A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. The American Journal of Psychiatry 176(11): 923\u2013930. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18101123","DOI":"10.1176\/appi.ajp.2019.18101123"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Dakwar E Levin F Hart CL et al. (2020) A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. The American Journal of Psychiatry 177(2): 125\u2013133. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19070684","DOI":"10.1176\/appi.ajp.2019.19070684"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"DiClemente CC Corno CM Graydon MM et al. (2017) Motivational interviewing enhancement and brief interventions over the last decade: A review of reviews of efficacy and effectiveness. Psychology of Addictive Behaviors 31(8): 862\u2013887. https:\/\/doi.org\/10.1037\/adb0000318","DOI":"10.1037\/adb0000318"},{"issue":"6","key":"e_1_3_2_13_1","first-page":"492","article-title":"What is the most effective nicotine replacement therapy?","volume":"52","author":"Diefenbach LJ","year":"2003","unstructured":"Diefenbach LJ, Smith PO, Nashelsky J (2003) What is the most effective nicotine replacement therapy? Journal of Family Practice 52(6): 492\u2013494.","journal-title":"Journal of Family Practice"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.9569017.x"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Grabski M McAndrew A Lawn W et al. (2022) Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. The American Journal of Psychiatry 179(2): 152\u2013162. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21030277","DOI":"10.1176\/appi.ajp.2021.21030277"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Heatherton TF Kozlowski LT Frecker RC et al. (1991) The Fagerstr\u00f6m Test for Nicotine Dependence: A revision of the Fagerstr\u00f6m Tolerance Questionnaire. British Journal of Addiction 86(9): 1119\u20131127. https:\/\/doi.org\/10.1111\/j.1360-0443.1991.tb01879.x","DOI":"10.1111\/j.1360-0443.1991.tb01879.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Holmes SE Finnema SJ Naganawa M et al. (2022) Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 27(4): 2273\u20132281. https:\/\/doi.org\/10.1038\/s41380-022-01465-2","DOI":"10.1038\/s41380-022-01465-2"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Johnson MW Garcia-Romeu A Cosimano MP et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28(11): 983\u2013992. https:\/\/doi.org\/10.1177\/0269881114548296","DOI":"10.1177\/0269881114548296"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Johnson MW Garcia-Romeu A Griffiths RR (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43(1): 55\u201360. https:\/\/doi.org\/10.3109\/00952990.2016.1170135","DOI":"10.3109\/00952990.2016.1170135"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Jones JL Mateus CF Malcolm RJ et al. (2018) Efficacy of ketamine in the treatment of substance use disorders: A systematic review. Frontiers in Psychiatry 9: 277. https:\/\/doi.org\/10.3389\/fpsyt.2018.00277","DOI":"10.3389\/fpsyt.2018.00277"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Kolp E Friedman HL Young MS et al. (2006) Ketamine enhanced psychotherapy: Preliminary clinical observations on its effectiveness in treating alcoholism. The Humanistic Psychologist 34(4): 399\u2013422. https:\/\/doi.org\/10.1207\/s15473333thp3404_7","DOI":"10.1207\/s15473333thp3404_7"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Krupitsky E Burakov A Romanova T et al. (2002) Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment 23(4): 273\u2013283. https:\/\/doi.org\/10.1016\/S0740-5472(02)00275-1","DOI":"10.1016\/S0740-5472(02)00275-1"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Krupitsky EM Grinenko AY (1997) Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs 29(2): 165\u2013183. https:\/\/doi.org\/10.1080\/02791072.1997.10400185","DOI":"10.1080\/02791072.1997.10400185"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Krupitsky EM Burakov AM Dunaevsky IV et al. (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. Journal of Psychoactive Drugs 39(1): 13\u201319. https:\/\/doi.org\/10.1080\/02791072.2007.10399860","DOI":"10.1080\/02791072.2007.10399860"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Levy D (2020) Abstract 57: Vulnerable populations disparities and the U.S. tobacco endgame. Circulation 141(Suppl 1): e57. https:\/\/doi.org\/10.1161\/circ.141.suppl_1.57","DOI":"10.1161\/circ.141.suppl_1.57"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Livingstone-Banks J Fanshawe TR Thomas KH et al. (2023) Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 5(5): CD006103. https:\/\/doi.org\/10.1002\/14651858.CD006103.pub8","DOI":"10.1002\/14651858.CD006103.pub8"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Ly C Greb AC Vargas MV et al. (2021) Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacology & Translational Science 4(2): 452\u2013460. https:\/\/doi.org\/10.1021\/acsptsci.0c00065","DOI":"10.1021\/acsptsci.0c00065"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"MacLean KA Leoutsakos JMS Johnson MW et al. (2012) Factor analysis of the Mystical Experience Questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion 51(4): 721\u2013737. https:\/\/doi.org\/10.1111\/j.1468-5906.2012.01685.x","DOI":"10.1111\/j.1468-5906.2012.01685.x"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"McConnaughy EA DiClemente C Prochaska JO (1983) University of Rhode Island Change Assessment Scale (URICA) short form for drugs. Unpublished manuscript.","DOI":"10.1037\/t01321-000"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Mendes FR Costa CDS Wiltenburg VD et al. (2022) Classic and non-classic psychedelics for substance use disorder: A review of their historic past and current research. Addiction Neuroscience 3: 100025. https:\/\/doi.org\/10.1016\/j.addicn.2022.100025","DOI":"10.1016\/j.addicn.2022.100025"},{"key":"e_1_3_2_31_1","volume-title":"Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence","author":"Miller WR","year":"1992","unstructured":"Miller WR and National Institute on Alcohol Abuse and Alcoholism (US) (1992) Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. National Institute on Alcohol Abuse and Alcoholism."},{"issue":"3","key":"e_1_3_2_32_1","first-page":"142","article-title":"Motivational interviewing or counseling, medical therapies or no intervention to improve tobacco cessation in adults and adolescents","volume":"110","author":"Norris AR","year":"2017","unstructured":"Norris AR, Miller JE (2017) Motivational interviewing or counseling, medical therapies or no intervention to improve tobacco cessation in adults and adolescents. The Journal of the Oklahoma State Medical Association 110(3): 142\u2013143.","journal-title":"The Journal of the Oklahoma State Medical Association"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"Olson DE (2018) Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. Journal of Experimental Neuroscience 12: 1179069518800508. https:\/\/doi.org\/10.1177\/1179069518800508","DOI":"10.1177\/1179069518800508"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Savalia NK Shao L-X Kwan AC (2021) A dendrite-focused framework for understanding the actions of ketamine and psychedelics. Trends in Neurosciences 44(4): 260\u2013275. https:\/\/doi.org\/10.1016\/j.tins.2020.11.008","DOI":"10.1016\/j.tins.2020.11.008"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Shao L-X Liao C Gregg I et al. (2021) Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109(16): 2535\u20132544.e4. https:\/\/doi.org\/10.1016\/j.neuron.2021.06.008","DOI":"10.1016\/j.neuron.2021.06.008"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Sharma R Batchelor R Sin J (2023) Psychedelic treatments for substance use disorder and substance misuse: A mixed methods systematic review. Journal of Psychoactive Drugs 55(5): 612\u2013630. https:\/\/doi.org\/10.1080\/02791072.2023.2190319","DOI":"10.1080\/02791072.2023.2190319"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-0357-5_3"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Tiffany ST Drobes DJ (1991) The development and initial validation of a questionnaire on smoking urges. British Journal of Addiction 86(11): 1467\u20131476. https:\/\/doi.org\/10.1111\/j.1360-0443.1991.tb01732.x","DOI":"10.1111\/j.1360-0443.1991.tb01732.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"Welsch SK Smith SS Wetter DW et al. (1999) Development and validation of the Wisconsin Smoking Withdrawal Scale. Experimental and Clinical Psychopharmacology 7(4): 354\u2013361. https:\/\/doi.org\/10.1037\/\/1064-1297.7.4.354","DOI":"10.1037\/1064-1297.7.4.354"},{"key":"e_1_3_2_40_1","unstructured":"World Health Organization (2024) Tobacco. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tobacco (accessed 15 May 2025)."},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","unstructured":"Zafar R Siegel M Harding R et al. (2023) Psychedelic therapy in the treatment of addiction: The past present and future. Frontiers in Psychiatry 14: 1183740. https:\/\/doi.org\/10.3389\/fpsyt.2023.1183740","DOI":"10.3389\/fpsyt.2023.1183740"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Zhornitsky S Oliva HNP Jayne LA et al. (2023) Changes in synaptic markers after administration of ketamine or psychedelics: A systematic scoping review. Frontiers in Psychiatry 14: 1197890. https:\/\/doi.org\/10.3389\/fpsyt.2023.1197890","DOI":"10.3389\/fpsyt.2023.1197890"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Zhou X Nonnemaker J Sherrill B et al. (2009) Attempts to quit smoking and relapse: Factors associated with success or failure from the ATTEMPT cohort study. Addictive Behaviors 34(4): 365\u2013373. https:\/\/doi.org\/10.1016\/j.addbeh.2008.11.013","DOI":"10.1016\/j.addbeh.2008.11.013"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261488486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261488486","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261488486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:47:20Z","timestamp":1790650040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261488486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":42,"alternative-id":["10.1177\/02698811261488486"],"URL":"https:\/\/doi.org\/10.1177\/02698811261488486","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"02698811261488486"}}